Table 4.

Molecular markers of resistance, all drug arms, Democratic Republic of the Congo therapeutic efficacy study, 2017

	All samples n (%)	Reinfection Day 0 n (%)	Recrudescence + reinfection day of failure n (%)
Pfk13
Successfully sequenced	486/523 (93)	251/263 (95)	235/260 (90)
Wild type	468 (96)	244 (97)	224 (95)
Synonymous*	17 (3)	7 (3)	10 (4)
Non-synonymous†	1 (0.2)	0 (0)	1 (0.4)
Pfmdr1 ‡
Successfully sequenced	462/466 (99.1)	204/206 (99)	258/260 (99.2)
N86	263 (57)	109 (53)	154 (60)
86N/Y	52 (11)	26 (13)	26 (10)
86Y	147 (32)	69 (34)	78 (30)
Y184	268 (58)	119 (58)	149 (58)
184Y/F	102 (22)	45 (22)	57 (22)
184F	92 (20)	40 (20)	52 (20)
D1246	379 (82)	166 (81)	213 (83)
1246D/Y	35 (8)	13 (6)	22 (9)
1246Y	48 (10)	25 (12)	23 (9)
NYD	232 (50)	89 (44)	143 (55)
NFD	141 (31)	53 (26)	88 (34)
NFY	20 (4)	7 (3)	13 (5)
NYY	31 (7)	10 (5)	21 (8)
YFD	69 (15)	27 (13)	42 (16)
YFY	0 (0)	0 (0)	0 (0)
YYD	130 (28)	48 (24)	82 (32)
YYY	20 (4)	20 (10)	0 (0)
Pfcrt § ‖
Successfully sequenced	85/85 (100)	38/38 (100)	47/47 (100)
M74	8 (9)	6 (16)	2 (4)
74M/I	2 (2)	2 (5)	0 (0)
74I	75 (88)	30 (79)	45 (96)
N75	10 (12)	8 (21)	2 (4)
75N/E	1 (1)	0 (0)	1 (2)
75E	74 (87)	30 (79)	44 (94)
K76	9 (11)	8 (21)	1 (2)
76K/T	1 (1)	0 (0)	1 (2)
76T	75 (88)	30 (79)	45 (96)
CVMNK	9 (11)	8 (21)	1 (2)
CVIET	75 (88)	30 (79)	45 (96)
CVMNT	1 (1)	0 (0)	1 (2)
CVINK	3 (6)	2 (6)	1 (2)

^*Synonymous mutations include P417P, C469C, R471R, S477S, T478T, G496G, Y511Y, R539R, and S576S.

^†Nonsynonymous mutation, S477Y.

^‡pfmdr1 haplotype constructed according to amino acids at positions 86, 184, and 1246; mixed infections included in numerator for each haplotype.

^§pfcrt haplotype constructed according to amino acids at positions 72, 73, 74, 75, and 76; mixed infections included in numerator for each haplotype.

^‖ All samples were wildtype for positions 72 (C) and 73 (D).